Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

Oncogene volume 34, pages 5411–5417 (2015)Cite this article

Subjects

Abstract

Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Leach DR, Krummel MF, Allison JP . Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734–1736.

    Article  CAS  PubMed  Google Scholar 

  2. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800.

    Article  CAS  PubMed  Google Scholar 

  3. Krummel MF, Allison JP . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459–465.

    Article  CAS  PubMed  Google Scholar 

  4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–2526.

    Article  CAS  PubMed  Google Scholar 

  6. Weber JS, Kahler KC, Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691–2697.

    Article  CAS  PubMed  Google Scholar 

  7. Quezada SA, Peggs KS, Curran MA, Allison JP . CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116: 1935–1945.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci USA 2008; 105: 3509–3514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 2013; 49: 24.

    Article  Google Scholar 

  10. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 2013; 1291: 1–13.

    Article  CAS  PubMed  Google Scholar 

  12. Fecher LA, Agarwala SS, Hodi FS, Weber JS . Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733–743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fadel F, El Karoui K, Knebelmann B . Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211–212.

    Article  CAS  PubMed  Google Scholar 

  14. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712–1717.

    Article  CAS  PubMed  Google Scholar 

  15. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155–164.

    Article  CAS  PubMed  Google Scholar 

  16. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 501–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 509–517.

    Article  CAS  PubMed  Google Scholar 

  18. Bristol-Myers Squibb Ipilimumab US prescribing information. http://www.yervoy.com/pdf/pi_yervoy.pdf2013.

  19. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28: 593–598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dillard T, Yedinak CG, Alumkal J, Fleseriu M . Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13: 29–38.

    Article  CAS  PubMed  Google Scholar 

  21. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004; 27: 478–479.

    Article  PubMed  Google Scholar 

  22. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P . Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008; 8: 9.

    PubMed  PubMed Central  Google Scholar 

  23. Wilgenhof S, Neyns B . Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011; 22: 991–993.

    Article  CAS  PubMed  Google Scholar 

  24. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bhatia S, Huber BR, Upton MP, Thompson JA . Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009; 32: 203–205.

    Article  PubMed  Google Scholar 

  26. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712–4717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372–8377.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741–750.

    Article  CAS  PubMed  Google Scholar 

  29. Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006; 142: 166–172.

    Article  CAS  PubMed  Google Scholar 

  30. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283–2289.

    Article  CAS  PubMed  Google Scholar 

  31. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10: 11.

    PubMed  PubMed Central  Google Scholar 

  32. Min L, Vaidya A, Becker C . Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164: 303–307.

    Article  CAS  PubMed  Google Scholar 

  33. Delyon J, Mateus C, Lambert T . Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365: 1747–1748.

    Article  CAS  PubMed  Google Scholar 

  34. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009; 7: 35.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695–1710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Alegre ML, Shiels H, Thompson CB, Gajewski TF . Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998; 161: 3347–3356.

    CAS  PubMed  Google Scholar 

  37. Ying H, Yang L, Qiao G, Li Z, Zhang L, Yin F et al. Cutting edge: CTLA-4—B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185: 1375–1378.

    Article  CAS  PubMed  Google Scholar 

  38. Garber K . Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012; 30: 475–477.

    Article  CAS  PubMed  Google Scholar 

  39. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105: 20410–20415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925–931.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15: 2507–2513.

    Article  CAS  PubMed  Google Scholar 

  42. Tarhini A . Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. Scientifica (Cairo) 2013; 2013: 857519.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

    J Gao, Q He, S Subudhi, A Aparicio, A Zurita-Saavedra, D H Lee & P Sharma

  2. Department of Endocrine Neoplasia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

    C Jimenez

  3. Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

    M Suarez-Almazor

  4. Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    P Sharma

Authors
  1. J Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Q He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Subudhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Aparicio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Zurita-Saavedra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Jimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Suarez-Almazor
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Sharma.

Ethics declarations

Competing interests

JG's work is supported by an American Society of Clinical Oncology Young Investigator Award and an NIH K12 grant. PS’s work is supported by an NIH R01 grant (1-R01 CA1633793-01), a research grant form Cancer Prevention Institute of Texas (RP120108), a Prostate Cancer Foundation Challenge Grant in Immunology and an American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant. PS also serves as a consultant for Bristol Myers-Squibb, Glaxo-Smith Kline and MedImmune/Astrazeneca. PS is also a founder and consultant for Jounce Therapeutics. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, J., He, Q., Subudhi, S. et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34, 5411–5417 (2015). https://doi.org/10.1038/onc.2015.5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2015.5

This article is cited by

Search

Advanced search

Quick links